Celsion Corporation

415 articles with Celsion Corporation

• Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update

  5/16/2022

  Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the quarter ended March 31, 2022, and provided an update on its clinical development program.

• Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates

  5/10/2022

  Celsion Corporation, a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, provided an update on the progress made in the Company’s two lead development programs.

• Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022

  5/9/2022

  Celsion Corporation announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, May 16, 2022 to discuss financial results for the first quarter ended March 31, 2022 and provide an update on product development programs.

• Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

  4/21/2022

  Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today presented its PLACCINE platform technology at the World Vaccine Congress taking place in Washington D.C.

• Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting

  4/14/2022

  Celsion Corporation and Medidata today announced that they presented their findings on the use of a Synthetic Control Arm Ⓡ (SCA) in a completed Phase Ib dose-escalating study of GEN-1 in the neoadjuvant treatment of patients with Stage III/IV ovarian cancer.

• Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress

  4/12/2022

  Celsion Corporation today announced it would highlight its PLACCINE platform technology in an oral presentation at the World Vaccine Congress taking place in Washington D.C. on April 18-21, 2022.

• CELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

  4/6/2022

  Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 1,328,274 shares of its common stock at a purchase price of $5.27 per share in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of $7.0 million before deducting placement agent fees and expenses.

• Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial

  4/6/2022

  Celsion Corporation (NASDAQ: CLSN) and Medidata, a Dassault Systèmes company, today announced that they will be presenting their findings on the use of a Synthetic Control ArmⓇ (SCA) in a completed Phase Ib dose-escalating study of GEN-1 in the neoadjuvant treatment of patients with Stage III/IV ovarian cancer (the OVATION 1 Study) at the Annual Meeting of the American Association for Cancer Research.

• Celsion Corporation Reported Cash Position of $56.9 million at December 31, 2021

  4/1/2022

  Celsion Corporation  today announced the company reported a cash position of $56.9 million as of December 31, 2021 during its earnings announcement on March 31, 2022.

• Celsion Corporation Reports 2021 Financial Results and Provides Business Update

  3/31/2022

  Celsion Corporation today announced financial results for the year ended December 31, 2021, and provided an update.

• Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022

  3/24/2022

  Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Thursday, March 31, 2022 to discuss financial results for the year ended December 31, 2021.

• Celsion Receives $1.4 Million from Sale of its New Jersey State Net Operating Losses

  2/28/2022

  Celsion Corporation, a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announced it has received $1.4 million in net cash proceeds from the sale of approximately $1.5 million of its unused New Jersey net operating losses.

• Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

  2/17/2022

  Celsion Corporation today announced that following a pre-planned interim safety review of 81 as treated patients randomized in the Phase I/II OVATION 2 Study with GEN-1.

• Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

  1/31/2022

  Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation DNA-based vaccines, announces it has engaged BIOQUAL, Inc., a preclinical testing contract research organization, to conduct a non-human primate (NHP) challenge study with Celsion’s DNA-based approach for a SARS-CoV-2 vaccine.

• Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock

  1/11/2022

  Celsion Corporation, a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 50,000 shares of Series A convertible redeemable preferred stock and 50,000 shares of Series B convertible redeemable preferred stock.

• Celsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update

  11/15/2021

  Celsion Corporation today announced financial results for the three and nine months ended September 30, 2021, and provided an update

• Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress

  10/15/2021

  Celsion Corporation, a clinical-stage development company focused on DNA mediated immunotherapy and next-generation nucleic vaccines, announces that a time of Monday, October 18, 2021 at 7:30 a.m. Eastern time has been set for Khursheed Anwer, Ph.D., executive vice president and chief science officer, to deliver his presentation at the International Vaccines Congress.

• Celsion Corporation Announces Oral Presentation at International Vaccines Congress

  10/12/2021

  Celsion Corporation, a clinical-stage development company focused on DNA mediated immunotherapy and next-generation nucleic vaccines, announces that Khursheed Anwer, Ph.D., executive vice president and chief science officer, will be presenting at the International Vaccines Congress being held virtually October 18-20, 2021.

• Celsion to Present at Three Investment Conferences in October 2021

  9/30/2021

  Celsion Corporation, a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announced that management will present at the following investment conferences in October.

• Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine

  9/17/2021

  Celsion Corporation and Hainan Poly Pharm Co. Ltd. announced an amendment to their existing contract manufacturing agreement to include development work for Celsion’s investigational DNA-based COVID-19 vaccine.